New hope for hard-to-treat ovarian cancer: phase 3 trial launches
NCT ID NCT07545460
First seen Apr 23, 2026 · Last updated May 24, 2026 · Updated 8 times
Summary
This study tests a new drug called BL-M07D1 against standard chemotherapy in people with HER2-positive ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 404 adults aged 18-75 will be randomly assigned to receive either BL-M07D1 or a doctor-chosen chemotherapy. The goal is to see if BL-M07D1 can slow cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.